A First-in-Human Study of FID-022 in Solid Tumor Patients

This is a first-in-human study of a new nutritional supplement called FID-022 designed specifically for patients with pancreatic cancer. The goal is to assess whether it is safe and feasible to use alongside standard pancreatic cancer treatment, aiming to support nutritional status and quality of life. **You may be eligible if...** - You are 18 or older - You have confirmed or strongly suspected pancreatic cancer (including various types of pancreatic cancer) - Your cancer may be at any stage — resectable, borderline, locally advanced, or metastatic - You are able to eat by mouth (no feeding tube or IV nutrition) - You can read and speak English - You are able to provide written consent **You may NOT be eligible if...** - You are pregnant or breastfeeding - You are currently using a feeding tube or receiving nutrition through a vein - You have significant fluid buildup in your abdomen (ascites) - You have a history of bowel obstruction or a condition that limits eating - You have a severe or uncontrolled psychiatric illness - You have other serious uncontrolled health conditions (such as active infection or heart/liver failure) Talk to your doctor to see if this trial is right for you.